Selected news coverage of the Resilient Drug Supply Project and its team members:
MedPage Today, Dec 7, 2020: "The US drug supply chain works well in the middle, but the beginning and end leave much room for improvement, according to Stephen Schondelmeyer, PharmD, PhD, of the University of Minnesota in Minneapolis."
Denver 7, Nov 30, 2020: "'We should, as a matter of national policy, have a map like we're building of the global drug supply from the beginning all the way until the drug reaches the patient,' Schondelmeyer said." Also reported by other Local Scripps Media sources, such as Fox 17 West Michigan and 4 KXLF Butte.
Bring Me the News, Nov 9, 2020: "Dr. Michael Osterholm, the director of the Center for Infectious Disease Research and Policy [and co-principal investigator of RDSP] at the University of Minnesota, has been named to President-elect Joe Biden's 13-member COVID-19 Advisory Board." Also reported on by CNN, The Washington Post, Fierce Healthcare, Becker's Hospital Review, Los Angeles Times, and others.
PharmTech, Nov 2, 2020: "A recent report from the Center for Infectious Disease Research and Policy at the University of Minnesota noted that 29 of 40 critical drugs used to treat patients with COVID-19 have experienced shortages. ... The pandemic may kick-start a number of changes in the way drugs are made. Identifying and qualifying the supply chain deserves a top spot on the list."
Star Tribune, Oct 31, 2020: "Minnesota’s long history with HMOs such as HealthPartners and Medica also pushed out a lot of independents, said Stephen Schondelmeyer, professor of pharmaceutical economics at the University of Minnesota. 'When health systems like HealthEast and Essentia got into retail pharmacy, it looked like they were community pharmacies but they were not independently owned,' he said. 'These health systems and PBMs push their patients to their own pharmacies.'"
The Washington Post, Oct 23, 2020: "A report this week by Osterholm's center showed shortages in 29 of the 40 basic but critical drugs used for covid-19 patients."
CNN, Oct 22, 2020: "'The urgency with the drug shortage supply issue is related directly to the major increase in COVID-19 cases that we will experience in the coming months,' Michael Osterholm, the director of CIDRAP, said in a news release. ... The drug shortage in the U.S. isn't new and remain a 'perennial problem,' the authors wrote." Also covered by Becker's Hospital Review, The Hill, and the University of Minnesota.
US News & World Report, Oct 22, 2020: "The COVID-19 pandemic worsened global disruption of the supply chain, and that exacerbated shortages of nearly 40% of the drugs (including epinephrine, the asthma inhaler albuterol and certain antibiotics) considered essential for critical care, according to a March 2020 analysis by University of Minnesota researchers."
STAT, Oct 21, 2020: "'The supply chain has already been stressed over the past years, but as we go through the fall and into the winter, we're going to have some real challenges' thanks to Covid-19, said Michael Osterholm, director of CIDRAP and co-principal investigator of the center's Resilient Drug Supply Project. ... As examples, they foresee the possibility of a five-fold jump in demand for midazolam, a commonly used sedative, and a 10-fold increase in the use of a muscle relaxant known as cisatracurium."
Click on the buttons to open the collapsible content.
Science, Jun 21, 2020: "There aren't a lot of [unused] plants that can make sterile injectables of anything, let alone dexamethasone, so I'm not sure how much capacity they really have,' he [Stephen Schondelmeyer] says. Ramping up supply 'takes a lot of time, even if the world was normal and sane, let alone during COVID.'" Also reported in Inverse.
Quartz, May 12, 2020: "Until now, companies have only had to report shortages in the finished dose to the FDA. The lists are helpful, said Professor Stephen Schondelmeyer, from the University of Minnesota's College of Pharmacy, but the reasons for shortages are 'very cursory and not really descriptive of what really happened behind the scenes.' ... At present, pharmacists are not able to tell if there will be a shortage for two weeks or for six months."
CBS, May 7, 2020: "A list put together by the University of Minnesota's Resilient Drug Supply Project shows that 32 out of 40 drugs deemed critical for treatment of COVID-19 patients are in short supply. ... 'We had drugs on the shortage list for more than two decades,' University of Minnesota Professor Stephen Schondelmeyer told CBS News' Anna Werner. 'COVID-19 has kind of brought this to light.'" Also reported in PharmTech and Becker's Hospital Review.
Michigan Radio, Apr 17, 2020: "'Generally wholesalers only have a month or two of stock on hand,' said Dave Margraf, a pharmaceutical research scientist at the University of Minnesota's Center for Infectious Disease Research and Policy. 'Once that month is over, is there enough coming in from overseas and U.S. manufacturers to meet a second dip in the drugs we have? This is an unknown.'"
Spikes in demand from coronavirus patients are creating shortages of asthma drugs and sedatives for ventilator patients
The Washington Post, Apr 12, 2020: "The shortages show how a lack of basic information is hurting U.S. planning and readiness for a variety of disasters, said Stephen Schondelmeyer, a professor of pharmaceutical economics in the College of Pharmacy at the University of Minnesota."
The New York Times, Apr 2, 2020: "'Out of 21 antibiotics that would be critical for treating secondary infections in Covid-19 patients, 18 antibiotics have greater than 80 percent of their supply coming out of either China, India or Italy—all places that have had production disruptions,' said Stephen Schondelmeyer, a professor at the University of Minnesota's College of Pharmacy who is a co-leader of the Resilient Drug Supply Project, which aims to provide a detailed map of the supply chain for important drugs used in the United States. Another factor that can affect the global supply chain is when countries ban export of certain drugs, either because of the trade wars or because they want to ensure supply for their own citizens, Mr. Schondelmeyer said."
University of Minnesota press release, Mar 26, 2020: "'With the COVID-19 pandemic expected to last many more months ... we call upon the pharmaceutical companies and their partners to publicly come forward with current inventor levels and information on the status and relative resiliency of their critical drug supply chains,' said Michael T. Osterholm." Also covered by DrugWatch.
Kare 11, Feb 28, 2020: "'If we do have coronavirus cases taking place in the US, people may want to minimize being out and about,' said Stephen Schondelmeyer, professor of pharmaceutical economics at the UofM. 'You should at least have a full month supply and, when possible, talk to your doctor and your pharmacist and see if you can get a 90 day supply.'"
Star Tribune, Feb 19, 2020: "Dr. Stephen Schondelmeyer, the task force's other co-chair, said he has been studying the local drug marketplace for 45 years. ... In the first weeks of 2020, he said 2,800 drugs saw price increases, with 200 going up more than 10%. A common pill to treat coughs and colds went from $22 to $213 per pill.'"
Star Tribune, Jan 19, 2019: "The center this week announced a $5.4 million gift from the Walton Family Foundation—the charitable arm of the family behind the Walmart retain chain—to study weak links in the nation’s prescription drug pipeline. 'We don't pretend we're going to fix it [the drug shortages] yet,' Osterholm said in an interview. 'We've just got to get people to understand the vulnerability.'" Also covered by KTSP/5 Eyewitness News, CBS Minnesota, and the University of Minnesota.